This study and related literature have confirmed that serum IGF-I and its related molecules (such as IGFBP-3 and pregnancy-associated plasma protein-A [PAPP-A]) are closely associated with the risk of prostate cancer, especially playing an important role in risk stratification and early warning. This evidence concerns the gene PAPPA and prostate carcinoma.